(Q35192213)

7 August 2017

1 reference

title

Cytokines as clinical adjuvants: how far are we? (English)

1 reference

7 August 2017

François Villinger

1

1 reference

7 August 2017

publication date

1 April 2003

1 reference

Expert Review of Vaccines

7 August 2017

published in

1 reference

7 August 2017

volume

2

1 reference

7 August 2017

issue

2

1 reference

7 August 2017

page(s)

317-326

1 reference

GM-CSF-based cellular vaccines: a review of the clinical experience

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.317

The use of dendritic cells in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.317

Exploiting dendritic cells to improve vaccine efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.317

Targeting early events in T cell activation to construct improved vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.317

Poor response to interferon treatment for chronic hepatitis C in human immunodeficiency virus-infected haemophiliacs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.317

Increased thymic mass and circulating naive CD4 T cells in HIV-1-infected adults treated with growth hormone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.317

Interferon-alpha in tumor immunity and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.317

Antigen presentation by MHC class I and its regulation by interferon gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.317

Stimulation of naïve and memory T cells by cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.317

Cellular responses to interferon-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.317

Interferon--a major regulator of natural killer cell-mediated cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.317

Type I interferons and limitin: a comparison of structures, receptors, and functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.317

Interferon-gamma therapy: evaluation of routes of administration and delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.317

Use of adjuvant therapy in cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.317

Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.317

Pilot study of interferon alpha high-dose induction therapy in combination with ribavirin for chronic hepatitis C in HIV-co-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.317

Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.317

Modulating the immune response with dendritic cells and their growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.317

Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.317

Granulocyte macrophage colony-stimulating factor: current practice and novel approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.317

Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.317

Successful induction of immune responses against mutant ras in melanoma patients using intradermal injection of peptides and GM-CSF as adjuvant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.317

GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.317

Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.317

Toxicity of immunotherapy with interleukin-2 and lymphokine-activated killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.317

Interleukin-12 in anti-tumor immunity and immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.317

A Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.317

A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.317

Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-alpha plus IL-2 and IL-12).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.317

A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.317

21 January 2018

Identifiers

DOI

10.1586/14760584.2.2.317

1 reference

7 August 2017

1 reference